Template:Epiglottitis Antibiotics: Difference between revisions

(Convert to {{AntibioticDose}} for SMW antibiotic-disease linking)
(Add pediatric immunocompetent and immunocompromised dosing)
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:


====Immunocompetent====
====Immunocompetent====
*{{AntibioticDose|drug=Ceftriaxone|dose=2gm IV once daily|context=Immunocompetent}} (first line) OR
*{{AntibioticDose|disease=Epiglottitis|drug=Ceftriaxone|dose=2gm IV once daily|context=Immunocompetent}} (first line) OR
*{{AntibioticDose|drug=Cefotaxime|dose=2gm (50mg/kg) IV three times daily|context=Immunocompetent}} OR
*{{AntibioticDose|disease=Epiglottitis|drug=Cefotaxime|dose=2gm (50mg/kg) IV three times daily|context=Immunocompetent}} OR
*{{AntibioticDose|drug=Ampicillin/Sulbactam|dose=3g (50mg/kg) IV q 6 hours|context=Immunocompetent}} OR
*{{AntibioticDose|disease=Epiglottitis|drug=Ampicillin/Sulbactam|dose=3g (50mg/kg) IV q 6 hours|context=Immunocompetent}} OR
*{{AntibioticDose|drug=Levofloxacin|dose=750mg IV once daily|context=Immunocompetent}}
*{{AntibioticDose|disease=Epiglottitis|drug=Levofloxacin|dose=750mg IV once daily|context=Immunocompetent}}
*Consider {{AntibioticDose|drug=Vancomycin|dose=15-20mg/kg IV|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>
*Consider {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15-20mg/kg IV|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>


====Immunocompromised====
====Immunocompromised====
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
*{{AntibioticDose|drug=Cefepime|dose=2g (50/kg) IV q8 hours|context=Immunocompromised}} AND {{AntibioticDose|drug=Vancomycin|dose=15mg/kg IV q6 hours|context=Immunocompromised}}
*{{AntibioticDose|disease=Epiglottitis|drug=Cefepime|dose=2g (50/kg) IV q8 hours|context=Immunocompromised}} AND {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6 hours|context=Immunocompromised}}
 
====Pediatric Immunocompetent====
*{{AntibioticDose|disease=Epiglottitis|drug=Ceftriaxone|dose=50-100mg/kg IV daily (max 2g)|context=Pediatric Immunocompetent|population=Pediatric}} (first line) OR
*{{AntibioticDose|disease=Epiglottitis|drug=Cefotaxime|dose=50mg/kg IV q8hrs (max 2g/dose)|context=Pediatric Immunocompetent|population=Pediatric}} OR
*{{AntibioticDose|disease=Epiglottitis|drug=Ampicillin/Sulbactam|dose=50mg/kg IV q6hrs (max 3g/dose)|context=Pediatric Immunocompetent|population=Pediatric}}
*Consider {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6hrs|context=Pediatric, MRSA risk|population=Pediatric}} if risk of [[MRSA]]
 
====Pediatric Immunocompromised====
*{{AntibioticDose|disease=Epiglottitis|drug=Cefepime|dose=50mg/kg IV q8hrs (max 2g)|context=Pediatric Immunocompromised|population=Pediatric}} AND {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6hrs|context=Pediatric Immunocompromised|population=Pediatric}}

Latest revision as of 12:52, 20 March 2026

Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae

Immunocompetent

Immunocompromised

Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans

Pediatric Immunocompetent

Pediatric Immunocompromised

  1. Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.